Organon & Co.

OGN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Assets
Cash & Equivalents $574.0M $675.0M $693.0M $706.0M $737.0M $12.0M
Accounts Receivable $1.33B $1.36B $1.74B $1.48B $1.38B $1.04B
Inventory $1.41B $1.32B $1.32B $1.00B $915.0M $913.0M
Total Current Assets $4.35B $4.35B $4.51B $3.93B $3.76B $3.57B
Property, Plant & Equipment $1.30B $1.17B $1.18B $1.02B $973.0M $984.0M
Goodwill $4.15B $4.68B $4.60B $4.60B $4.60B $4.60B
Intangible Assets (Excl. Goodwill) $1.13B $1.41B $533.0M $649.0M $651.0M $503.0M
Total Assets $12.87B $13.10B $12.06B $10.96B $10.68B $10.11B
Liabilities
Accounts Payable $952.0M $1.15B $1.31B $1.13B $1.38B $259.0M
Total Current Liabilities $2.39B $2.72B $2.92B $2.51B $2.60B $2.67B
Long-Term Debt $8.63B $8.86B $8.75B $8.91B $9.13B $0
Total Liabilities $12.12B $12.63B $12.13B $11.85B $12.19B $4.62B
Stockholders' Equity
Retained Earnings $1.11B $1.01B $443.0M $-331.0M $-998.0M $0
Total Stockholders' Equity $752.0M $472.0M $-70.0M $-892.0M $-1.51B $5.49B